[HTML][HTML] PTRF/cavin-1 and MIF proteins are identified as non-small cell lung cancer biomarkers by label-free proteomics

…, E Calvo, MT Agulló-Ortuño, R López-Vacas… - PloS one, 2012 - journals.plos.org
With the completion of the human genome sequence, biomedical sciences have entered in
the “omics” era, mainly due to high-throughput genomics techniques and the recent …

[HTML][HTML] A novel approach to triple-negative breast cancer molecular classification reveals a luminal immune-positive subgroup with good prognoses

…, M Ferrer-Gómez, M Díaz-Almirón, R López-Vacas… - Scientific reports, 2019 - nature.com
Triple-negative breast cancer is a heterogeneous disease characterized by a lack of hormonal
receptors and HER2 overexpression. It is the only breast cancer subgroup that does not …

Combined label-free quantitative proteomics and microRNA expression analysis of breast cancer unravel molecular differences with clinical implications

…, JM Arevalillo, P Nanni, R López-Vacas… - Cancer research, 2015 - AACR
Better knowledge of the biology of breast cancer has allowed the use of new targeted therapies,
leading to improved outcome. High-throughput technologies allow deepening into the …

[HTML][HTML] Functional proteomics outlines the complexity of breast cancer molecular subtypes

…, J Berges-Soria, N Selevsek, R López-Vacas… - Scientific Reports, 2017 - nature.com
Breast cancer is a heterogeneous disease comprising a variety of entities with various
genetic backgrounds. Estrogen receptor-positive, human epidermal growth factor receptor 2-…

[HTML][HTML] Comprehensive characterization of the mutational landscape in localized anal squamous cell carcinoma

…, G Laura, M Mendiola, C Peña, R Lopez-Vacas… - Translational …, 2020 - Elsevier
Anal squamous cell carcinoma (ASCC) is a rare neoplasm. Chemoradiotherapy is the
standard of care, with no therapeutic advances achieved over the past three decades. Thus, a …

[HTML][HTML] Prediction of adjuvant chemotherapy response in triple negative breast cancer with discovery and targeted proteomics

…, G Prado-Vázquez, C Chiva, R López-Vacas… - PLoS …, 2017 - journals.plos.org
Background Triple-negative breast cancer (TNBC) accounts for 15–20% of all breast cancers
and usually requires the administration of adjuvant chemotherapy after surgery but even …

Shotgun proteomics of archival triple‐negative breast cancer samples

…, NI Ferrer, E Ciruelos, R LópezVacas… - PROTEOMICS …, 2013 - Wiley Online Library
Purpose Triple‐negative breast cancer ( TNBC ) accounts for 15–20% of all breast cancers,
and has a worse prognosis compared with hormone receptor‐positive disease. Its …

[HTML][HTML] Synergistic effect of antimetabolic and chemotherapy drugs in triple-negative breast cancer

…, A Gámez-Pozo, I Dapía, R López-Vacas… - Biomedicine & …, 2022 - Elsevier
The triple-negative breast cancer (TNBC) subtype comprises approximately 15% of all breast
cancers and is associated with poor long-term outcomes. Classical chemotherapy remains …

Functional proteomics of colon cancer Consensus Molecular Subtypes

…, D Viñal, L Kunz, R López-Vacas… - British Journal of …, 2024 - nature.com
Background The Colorectal Cancer Subtyping Consortium established four Consensus
Molecular Subtypes (CMS) in colorectal cancer: CMS1 (microsatellite-instability [MSI], Immune), …

[HTML][HTML] Molecular characterization of breast cancer cell response to metabolic drugs

…, H Navarro, R Aras-López, I Dapía, R López-Vacas… - Oncotarget, 2018 - ncbi.nlm.nih.gov
Metabolic reprogramming is a hallmark of cancer. It has been described that breast cancer
subtypes present metabolism differences and this fact enables the possibility of using …